Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC

被引：0
|
作者：
Pinto, L. Masfarre [1 ]
Rocha, P. [2 ]
Clave, S. [3 ]
Gorro, N. Navarro [4 ]
Sanchez, I. [3 ]
Giner, M. [5 ]
Lloret, A. Corbera [4 ]
Garcia, A. Taus [4 ]
Parreira, A. S. D. F. M. [6 ]
Paricio, B. Bellosillo [7 ]
Arriola, E. [1 ]
机构：
[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain
[2] Hosp Mar Parc Salut Mar, Translat Mol Pathol Dept, Barcelona, Spain
[3] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Mar Parc Salut Mar, Barcelona, Spain
[6] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain
[7] Hosp Mar Parc Salut Mar, Dept Mol Biol, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：S145 / S146
页数：2
相关论文
共 50 条
  • [41] Overcoming adaptive resistance to KRAS G12C inhibitors
    Adachi, Yuta
    Niitsu, Hiroaki
    Yamaguchi, Rui
    Ebi, Hiromichi
    CANCER SCIENCE, 2024, 115 : 110 - 110
  • [42] Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
    Cheema, Parneet K.
    Banerji, Shantanu O.
    Blais, Normand
    Chu, Quincy S. C.
    Juergens, Rosalyn A.
    Leighl, Natasha B.
    Sacher, Adrian
    Sheffield, Brandon S.
    Snow, Stephanie
    Vincent, Mark
    Wheatley-Price, Paul F.
    Yip, Stephen
    Melosky, Barbara L.
    CURRENT ONCOLOGY, 2023, 30 (07) : 6473 - 6496
  • [43] Resistenzmechanismen beim KRAS-G12C-mutierten KarzinomResistance mechanisms in KRAS-G12C-mutated cancer
    Asmae Gassa
    Filiz Özkan
    David Ast
    Thorsten Wahlers
    Christiane Bruns
    Hakan Alakus
    Der Onkologe, 2021, 27 (12): : 1243 - 1244
  • [44] KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
    Masfarre, L.
    Rocha, P.
    Clave, S.
    Moliner, L.
    Navarro-Gorro, N.
    Rios-Hoyo, A.
    Sanchez, I.
    Giner, M.
    Corbera, A.
    Taus, A.
    Bellosillo, B.
    Arriola, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S109 - S109
  • [45] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
  • [46] Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C-Mutated Colorectal Cancer: A Case Report
    Morris, Linda
    Pappas, Leontios
    Pandey, Aditya
    Singh, Harshabad
    Klempner, Samuel
    Caughey, Bennett
    JCO PRECISION ONCOLOGY, 2024, 8
  • [47] KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
    Eser, Metin
    Hekimoglu, Gulam
    Yarar, Murat Hakki
    Canbek, Sezin
    Ozcelik, Melike
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [48] KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis
    Manoharan, Aysswarya
    Kareff, Samuel A.
    Ramos, Leana M.
    El-Abbar, Nora A.
    Lopes, Gilberto
    Rodriguez, Estelamari
    CANCER RESEARCH, 2023, 83 (07)
  • [49] Therapierefraktäres kolorektales Karzinom mit KRAS-G12C-MutationTreatment-refractory colorectal cancer with KRAS G12C mutation
    Milan J. M. Hartmann
    Hakan Alakus
    Die Onkologie, 2024, 30 (6) : 521 - 522
  • [50] Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down
    Hobbs, G. Aaron
    Wittinghofer, Alfred
    Der, Channing J.
    CANCER CELL, 2016, 29 (03) : 251 - 253
12345